RPRX News & Events

Royalty Pharma (RPRX) announced a research and development co-funding agreement with Johnson & Johnson (JNJ) for a total of $500M in 2026 and 2027 to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. JNJ-4804 is a novel co-antibody therapy that blocks the complementary interleukin-23 and tumor necrosis factor pathways, delivering synergistic effects on the pathogenesis of chronic immune-mediated diseases.

Royalty Pharma announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Sun will be based in Hong Kong and lead the company's royalty business in Asia.